Literature DB >> 34911064

Prolonged Washout Period for Avoiding Azilsartan-Induced Refractory Hypotension During General Anesthesia for a Patient With Renal Impairment.

Takayuki Hojo1, Yukifumi Kimura1, Keiji Hashimoto1, Takahito Teshirogi1, Toshiaki Fujisawa1.   

Abstract

Angiotensin receptor blockers (ARBs) are widely used to treat hypertension, but severe refractory hypotension during general anesthesia is a well-known complication associated with the continuation of ARBs during the perioperative period. It has therefore been recommended that ARBs be withheld for 24 hours before induction of general anesthesia. However, impaired renal function affects the pharmacokinetics of each ARB differently. The half-life of azilsartan is prolonged in accordance with the degree of renal impairment. Herein, we describe a patient with chronic kidney disease grade 3B who experienced severe refractory hypotension after induction of general anesthesia requiring administration of dopamine following inadequate responses to ephedrine and phenylephrine despite a 24-hour azilsartan washout period. When the same patient underwent general anesthesia for a subsequent surgery, azilsartan was withheld for 48 hours before induction, resulting in mild intraoperative hypotension that responded adequately to phenylephrine. Severe refractory hypotension during general anesthesia cannot always be avoided by holding azilsartan for 24 hours in patients with significant renal impairment. Therefore, a longer washout period may be preferable for patients regularly taking azilsartan who also have concurrent substantial renal impairment.
© 2021 by the American Dental Society of Anesthesiology.

Entities:  

Keywords:  Angiotensin receptor blocker; Azilsartan; General anesthesia; Refractory hypotension; Renal impairment; Washout period

Mesh:

Substances:

Year:  2021        PMID: 34911064      PMCID: PMC8674853          DOI: 10.2344/anpr-68-02-08

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  10 in total

Review 1.  Management of hypotension associated with angiotensin-axis blockade and general anesthesia administration.

Authors:  Berend Mets
Journal:  J Cardiothorac Vasc Anesth       Date:  2012-07-31       Impact factor: 2.628

2.  Refractory Hypotension During General Anesthesia Despite Withholding Telmisartan.

Authors:  Takayuki Hojo; Makiko Shibuya; Yukifumi Kimura; Yuki Otsuka; Toshiaki Fujisawa
Journal:  Anesth Prog       Date:  2020-06-01

3.  The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists.

Authors:  S M Brabant; M Bertrand; D Eyraud; P L Darmon; P Coriat
Journal:  Anesth Analg       Date:  1999-12       Impact factor: 5.108

4.  Should the angiotensin II antagonists be discontinued before surgery?

Authors:  M Bertrand; G Godet; K Meersschaert; L Brun; E Salcedo; P Coriat
Journal:  Anesth Analg       Date:  2001-01       Impact factor: 5.108

5.  Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.

Authors:  Pavel S Roshanov; Bram Rochwerg; Ameen Patel; Omid Salehian; Emmanuelle Duceppe; Emilie P Belley-Côté; Gordon H Guyatt; Daniel I Sessler; Yannick Le Manach; Flavia K Borges; Vikas Tandon; Andrew Worster; Alexandra Thompson; Mithin Koshy; Breagh Devereaux; Frederick A Spencer; Robert D Sanders; Erin N Sloan; Erin E Morley; James Paul; Karen E Raymer; Zubin Punthakee; P J Devereaux
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

Review 6.  A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.

Authors:  Martin C Michel; Carolyn Foster; Hans R Brunner; Lisheng Liu
Journal:  Pharmacol Rev       Date:  2013-03-13       Impact factor: 25.468

7.  A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery.

Authors:  Caryl Hollmann; Nicole L Fernandes; Bruce M Biccard
Journal:  Anesth Analg       Date:  2018-09       Impact factor: 5.108

8.  Neurocirculatory responses to sevoflurane in humans. A comparison to desflurane.

Authors:  T J Ebert; M Muzi; C W Lopatka
Journal:  Anesthesiology       Date:  1995-07       Impact factor: 7.892

9.  Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment.

Authors:  Richard A Preston; Aziz Karim; Caroline Dudkowski; Zhen Zhao; Dyal Garg; Oliver Lenz; Domenic A Sica
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

10.  Refractory hypotension during general anesthesia despite preoperative discontinuation of an angiotensin receptor blocker.

Authors:  Raha Nabbi; Harvey J Woehlck; Matthias L Riess
Journal:  F1000Res       Date:  2013-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.